MIR-142-5p and miR-9 may be involved in squamous lung cancer by regulating cell cycle related genes

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 23, 2013, Pages 3213-3220

  Su, Y H ^a   Zhou, Z ^a   Yang, K P ^a   Wang, X G ^a   Zhu, Y ^a   Fa, X E ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Differentially expressed gene; Function enrichment analysis; MicroRNA; Regulatory network; Squamous lung cancer

Indexed keywords

MICRORNA; MICRORNA 142 5P; MICRORNA 9; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CARCINOGENESIS; CELL CYCLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; HUMAN; LUNG SQUAMOUS CELL CARCINOMA; TUMOR GENE; UPREGULATION;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; TUMOR MARKERS, BIOLOGICAL;

EID: 84891775281     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. TANOUE LT, DETTERBECK FC. New TNM classification for non-small-cell lung cancer. Expert Rev Anti-cancer Ther 2009; 9: 413-423.
2. TOKUMO M, TOYOOKA S, KIURA K, SHIGEMATSU H, TOMII K, AOE M, ICHIMURA K, TSUDA T, YANO M, TSUKUDA K, TABATA M, UEOKA H, TANIMOTO M, DATE H, GAZDAR AF, SHIMIZU N. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005; 11: 1167-1173.
3. WEISS J, SOS ML, SEIDEL D, PEIFER M, ZANDER T, HEUCKMANN JM, ULLRICH RT, MENON R, MAIER S, SOLTERMANN A, MOCH H, WAGENER P, FISCHER F, HEYNCK S, KOKER M, SCHÖTTLE J, LEENDERS F, GABLER F, DABOW I, QUERINGS S, HEUKAMP LC, BALKE-WANT H, ANSÉN S, RAUH D, BAESSMANN I, ALTMÜLLER J, WAINER Z, CONRON M, WRIGHT G, RUSSELL P, SOLOMON B, BRAMBILLA E, BRAMBILLA C, LORIMIER P, SOLLBERG S, BRUSTUGUN OT, ENGEL-RIEDEL W, LUDWIG C, PETERSEN I, S ÄNGER J, CLEMENT J, GROEN H, TIMENS W, SIETSMA H, THUNNISSEN E, SMIT E, HEIDEMAN D, CAPPUZZO F, LIGORIO C, DAMIANI S, HALLEK M, BEROUKHIM R, PAO W, KLEBL B, BAUMANN M, BUETTNER R, ERNESTUS K, STOELBEN E, WOLF J, NÜRNBERG P, PERNER S, THOMAS RK. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2: 62ra93-62ra93.
4. PAEZ JG, JANNE PA, LEE JC, TRACY S, GREULICH H, GABRIEL S, HERMAN P, KAYE FJ, LINDEMAN N, BOGGON TJ, NAOKI K, SASAKI H, FUJII Y, ECK MJ, SELLERS WR, JOHNSON BE, MEYERSON M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
5. HOELLER D, HECKER C-M, DIKIC I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 2006; 6: 776-788.
6. DRANOFF G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4: 11-22.
7. BARTEL DP. Micrornas: target recognition and regulatory functions. Cell 2009; 136: 215-233.
8. BARTEL DP. Micrornas: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
9. BEREZIKOV E, GURYEV V, VAN DE BELT J, WIENHOLDS E, PLASTERK RH, CUPPEN E. Phylogenetic shadowing and computational identification of human microrna genes. Cell 2005; 120:21-24
10. YANAIHARA N, CAPLEN N, BOWMAN E, SEIKE M, KUMAMOTO K, YI M, STEPHENS RM, OKAMOTO A, YOKOTA J, TANAKA T, CALIN GA, LIU CG, CROCE CM, HARRIS CC. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-198.
11. ESQUELA-KERSCHER A, SLACK FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
12. PUYOL M, MARTÍN A, DUBUS P, MULERO F, PIZCUETA P, KHAN G, GUERRA C, SANTAMARÍA D, BARBACID M. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010; 18: 63-73.
13. DERISI J, PENLAND L, BROWN PO, BITTNER ML, MELTZER PS, RAY M, CHEN Y, SU YA, TRENT JM. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996; 14: 457-460.
14. WACHI S, YONEDA K, WU R. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics 2005; 21:4205-4208
15. TROYANSKAYA O, CANTOR M, SHERLOCK G, BROWN P, HASTIE T, TIBSHIRANI R, BOTSTEIN D, ALTMAN RB. Missing value estimation methods for DNA microarrays. Bioinformatics 2001; 17: 520-525.
16. FUJITA A, SATO JR, RODRIGUES LDE O, FERREIRA CE, SOGAYAR MC. Evaluating different methods of microarray data normalization.BMC Bioinformatics 2006; 7: 469.
17. POLLARD KS, DUDOIT S, VAN DER LAAN MJ. Multiple testing procedures: R multtest package and applications to genomics. In: Bioinformatics and Computational Biology Solutio??? Using R and Bioconductor. Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S, Editors. Springer Statistics for Biology and Health Series, 2005; 251-272.
18. BENJAMINI Y, HOCHBERG Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statist Society. Series B (Methodological) 1995: 289-300.
19. EISEN MB, SPELLMAN PT, BROWN PO, BOTSTEIN D. Cluster analysis and display of genome-wide expression patterns. Proc Nat Acad Sci 1998; 95: 14863-14868.
20. NAM D, KIM S-Y. Gene-set approach for expression pattern analysis.Briefings Bioinform 2008; 9: 189-197.
21. DA WEI HUANG BTS, LEMPICKI RA. Systematic and integrative analysis of large gene lists using david bioinformatics resources. Nat Prot 2008; 4: 44-57.
22. ZHANG B, KIROV S, SNODDY J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 2005; 33: W741-W748.
23. DUNCAN D, PRODDUTURI N, ZHANG B. WebGestalt2: an updated and expanded version of the web-based gene set analysis toolkit. BMC Bioinformatics 2010; 11: P10.
24. LODISH HB, MATSUDAIRA A, KAISER P, KRIEGER C, SCOTT M, ZIPURKSY M. SL & DARNELL, J. (2004). Mol Cell Biol 5th ed.WH Freeman: New York, NY.
25. BLAGOSKLONNY MV, PARDEE AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 2001; 61: 4301-4305.
26. MISHINA T, DOSAKA-AKITA H, HOMMURA F, NISHI M, KOJIMA T, OGURA S, SHIMIZU M, KATOH H, KAWAKAMI Y. Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. Clin Cancer Res 2000; 6: 11-16.
27. HAYWARD DG, CLARKE RB, FARAGHER AJ, PILLAI MR, HAGAN IM, FRY AM. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res 2004; 64: 7370-7376.
28. HAYWARD DG, FRY AM. Nek2 kinase in chromosome instability and cancer. Cancer Lett 2006; 237: 155-166.
29. XU N, WU SD, WANG H, WANG Q, BAI CX. Involvement of FOXM1 in non-small cell lung cancer recurrence. Asian Pac J Cancer Prev 2012; 13: 4739-4743.
30. XU N, JIA D, CHEN W, WANG H, LIU F, GE H, ZHU X, SONG Y, ZHANG X, ZHANG D, GE D, BAI C. FOXM1 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor metastasis. PLoS One 2013; 8: e59412.
31. YANG C, CHEN H, YU L, SHAN L, XIE L, HU J, CHEN T, TAN Y. Inhibition of FOXM1 transcription factor suppresses cell proliferation and tumor growth of breast cancer. Cancer Gene Ther 2013; 20:117-124.
32. YOON CH, KIM MJ, LEE H, KIM RK, LIM EJ, YOO KC, LEE GH, CUI YH, OH YS, GYE MC, LEE YY, PARK IC, AN S, HWANG SG, PARK MJ, SUH Y, LEE SJ. PTTG1 oncogene promotes tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population. J Biol Chem 2012; 287: 19516-19527.
33. ZHU X, MAO Z, NA Y, GUO Y, WANG X, XIN D. Significance of pituitary tumor transforming gene 1 (PTTG1) in prostate cancer. Anticancer Res 2006; 26: 1253-1259.
34. HUANG SQ, LIAO QJ, WANG XW, XIN DQ, CHEN SX, WU QJ, YE G. RNAi-mediated knockdown of pituitary tumor-transforming gene-1 (PTTG1) suppresses the proliferation and invasive potential of PC3 human prostate cancer cells. Braz J Med Biol Res 2012; 45: 995-1001.
35. RIZZO A, WALDNER MJ, STOLFI C, SARRA M, FINA D, BECKER C, NEURATH MF, MACDONALD TT, PALLONE F, MONTELEONE G, FANTINI MC. Smad7 expression in T cells prevents colitis-associated cancer. Cancer Res 2011; 71: 7423-7432.
36. WANG P, FAN J, CHEN Z, MENG ZQ, LUO JM, LIN JH, ZHOU ZH, CHEN H, WANG K, XU ZD, LIU LM. Low-level expression of Smad7 correlates with lymph node metastasis and poor prognosis in patients with pancreatic cancer. Ann Surg Oncol 2009; 16: 826-835.
37. LO PK, LEE JS, LIANG X, HAN L, MORI T, FACKLER MJ, SADIK H, ARGANI P, PANDITA TK, SUKUMAR S. Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer. Cancer Res 2010; 70: 6047-6058.
38. HONG L, HAN Y, ZHANG H, LI M, GONG T, SUN L, WU K, ZHAO Q, FAN D. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010; 251: 1056.
39. TAKESHITA F, PATRAWALA L, OSAKI M, TAKAHASHI R-U, YAMAMOTO Y, KOSAKA N, KAWAMATA M, KELNAR K, BADER AG, BROWN D, OCHIYA T. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol The 2009; 18: 181-187.
40. TAKEICHI M. Cadherins in cancer: implications for invasion and metastasis.Curr Opin Cell Biol 1993; 5: 806-811.
41. ALMAND B, RESSER JR, LINDMAN B, NADAF S, CLARK JI, KWON ED, CARBONE DP, GABRILOVICH DI. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000; 6: 1755-1766.
42. GUPTA AK, MCKENNA WG, WEBER CN, FELDMAN MD, GOLDSMITH JD, MICK R, MACHTAY M, ROSENTHAL DI, BAKANAUSKAS VJ, CERNIGLIA GJ, BERNHARD EJ, WEBER RS, MUSCHEL RJ. Local recurrence in head and neck cancer relationship to radiation resistance and signal transduction. Clin Cancer Res 2002; 8: 885-892.
43. ZHANG X, YAN Z, ZHANG J, GONG L, LI W, CUI J, LIU Y, GAO Z, LI J, SHEN L, LU Y. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol 2011; 22: 2257-2266.
44. LIU X, SEMPERE LF, GALIMBERTI F, FREEMANTLE SJ, BLACK C, DRAGNEV KH, MA Y, FIERING S, MEMOLI V, LI H, DIRENZO J, KORC M, COLE CN, BAK M, KAUPPINEN S, DMITROVSKY E. Uncovering growth-suppressive micrornas in lung cancer. Clin Cancer Res 2009; 15: 1177-1183.
45. SEMPERE LF, LIU X, DMITROVSKY E. Tumor-suppressive micrornas in lung cancer: diagnostic and therapeutic opportunities. Sci World J 2009; 9: 626-628.
46. MA L, YOUNG J, PRABHALA H, PAN E, MESTDAGH P, MUTH D, TERUYA-FELDSTEIN J, REINHARDT F, ONDER TT, VALASTYAN S, WESTERMANN F, SPELEMAN F, VANDESOMPELE J, WEINBERG RA. miR-9, a MYC/ MYCN-activated microrna, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247-256.
47. NASS D, ROSENWALD S, MEIRI E, GILAD S, TABIBIANKEISSAR H, SCHLOSBERG A, KUKER H, SION-VARDY N, TOBAR A, KHARENKO O, SITBON E, LITHWICK YANAI G, ELYAKIM E, CHOLAKH H, GIBORI H, SPECTOR Y, BENTWICH Z, BARSHACK I, ROSENFELD N. MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol 2009; 19: 375-383.
48. LAIOS A, O'TOOLE S, FLAVIN R, MARTIN C, KELLY L, RING M, FINN SP, BARRETT C, LODA M, GLEESON N, D'ARCY T, MCGUINNESS E, SHEILS O, SHEPPARD B, O'LEARY J. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 2008; 7: 35.
49. HILDEBRANDT M, GU J, LIN J, YE Y, TAN W, TAMBOLI P, WOOD C, WU X. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 2010; 29: 5724-5728.